Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
47
References
0
Citations
NaN
KQI